In one aspect, an immunogen includes an immunogenic carrier comprising an RNA bacteriophage virus-like particle (VLP) and an antigenic SARS-CoV-2 stem-helix peptide linked to the immunogenic carrier. In another aspect, an immunogen includes an immunogenic carrier comprising an RNA bacteriophage virus-like particle (VLP) and an antigenic SARS-CoV-2 nucleocapsid (N) protein peptide linked to the immunogenic carrier. In one or more embodiments of either aspect, the immunogen may be a component of a pharmaceutical composition. In one or more embodiments of either aspect, the immunogen may be a component of a vaccine.

The present invention relates to bacteriophage therapy. More particularly, the present invention relates to novel bacteriophages having a high specificity against Escherichia coli strains, their manufacture, components thereof, compositions comprising the same and the uses thereof in phage therapy.

Provided herein are antibacterial compositions and methods of making and using the compositions.

Provided herein are antibacterial compositions and methods of making and using the compositions.

The present invention relates to novel bacteriophages specific to Klebsiella pneumoniae strains, and compositions comprising the same. Particularly, polypeptides and their coding nucleic acid molecule of the novel bacteriophages are provided. The invention also relates to applications of the novel bacteriophages and the polypeptides in the detection/treatment/prevention of infection caused by Klebsiella pneumoniae strains. Development of immunogen and vaccine on the basis of the polypeptides are also provided.

The present invention is in the field of molecular biology and is directed to novel reverse transcriptase enzymes and compositions, and to methods and kits for producing, amplifying, or sequencing nucleic acid molecules using these novel reverse transcriptase enzymes or compositions. In particular the Invention relates to a polymerase selected from the group of. a polymerase (O15) as encoded by a nucleic acid according to SEQ ID NO. 9 or a nucleic acid that is at least 98% identical thereto, a polymerase (O15) with the amino acid sequence according to SEQ ID NO: 10 or a polymerase that is at least 90% identical thereto, a polymerase (O57) as encoded by a nucleic acid according to SEQ ID NO. 11 or a nucleic acid that is at least 98% identical thereto, a polymerase (O57) with the amino acid sequence according to SEQ ID NO: 12 or a polymerase that is at least 90% identical thereto. a polymerase (O58) as encoded by a nucleic acid according to SEQ ID NO. 13 or a nucleic acid that is at least 98% identical thereto, and a polymerase (O58) with the amino acid sequence according to SEQ ID NO: 14 or a polymerase that is at least 90% identical thereto.

The present invention relates to novel bacteriophages specific to Klebsiella pneumoniae strains, and compositions comprising the same. Particularly, polypeptides and their coding nucleic acid molecule of the novel bacteriophages are provided. The invention also relates to applications of the novel bacteriophages and the polypeptides in the detection/treatment/prevention of infection caused by Klebsiella pneumoniae strains. Development of immunogen and vaccine on the basis of the polypeptides are also provided.

Provided herein are antibacterial compositions and methods of making and using the compositions.

The disclosure is related to antimicrobial peptides which are derived from the phage of Acinetobacter baumannii. The disclosure also provides antimicrobial compositions and methods of sterilizing microorganism in vitro.

To control plant diseases caused by Xanthomonas spp., a novel bacteriophage exhibiting bacteriolysis activity specifically on Xanthomonas spp. was isolated. Thus, developed and provided is a plant disease control composition containing the bacteriophage as an active ingredient. Provided are a bacteriolytic agent containing a bacteriophage that has a novel genomic DNA sequence and exhibits bacteriolysis activity specifically on Xanthomonas spp., and a plant disease control composition containing the same as an active ingredient.